Engineered immune cells take on tough blood cancers in new trial

This study tested a special immune cell treatment called anti-CD19 CAR-T therapy in 58 adults with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that had returned or not responded to prior treatments. The therapy involves taking a patient's own immune cells, modifying them in a lab to target cancer cells, and giving them back through an IV. The main goals were to check safety and see how well the treatment controls the cancer. While promising, this approach typically requires ongoing monitoring and may involve long-term medication, so it is not considered a cure.